New treatment methods for acute myeloid leukemia using targeted radiation therapy
Official title: Novel Approaches to CD33-Directed Radioimmunotherapy
Funded at Fred Hutchinson Cancer Center · NIH-10977966 · Data updated 2026-11-12
This study is looking at a new way to treat acute myeloid leukemia (AML) using a special type of radiation that targets leukemia cells, which could make treatments safer and more effective for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $657,666 |
| NIH project number | 4R37CA240832-07 |
| Project ID | NIH-10977966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who express the CD33 protein on their leukemia cells.
✕Less likely to help
Patients with acute myeloid leukemia who do not express CD33 or have other types of leukemia may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for acute myeloid leukemia (AML) by using targeted radiation delivered through antibodies that specifically bind to CD33, a protein found on leukemia cells. The study aims to improve upon existing treatments by utilizing astatine-211, a radioactive substance with a shorter half-life and fewer harmful byproducts compared to previous options. By testing these new therapies in humanized mice, the researchers hope to enhance the effectiveness and safety of CD33-directed radioimmunotherapy, potentially leading to better outcomes for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promise with antibody-drug conjugates targeting CD33, but this approach using astatine-211 represents a novel strategy that has not been extensively tested.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Walter, Roland Bruno — Fred Hutchinson Cancer Center
- Study coordinator: Walter, Roland Bruno
Related research
Other NIH-funded projects on the same topics.
-
How brain glia prune neuron fragments in a worm model
Researchers study how brain support cells called glia remove pieces of living neurons in a tiny worm to learn about brain aging and diseases like Alzheimer's.
-
Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
-
Personalized cancer drug testing on patient tumor cells
Aiming to test many FDA-approved cancer drugs on a patient’s own tumor cells to identify effective options when standard therapies fail.
-
MOSAAIC: Using health records to track heart disease in Asian American Communities
A big, dedicated effort is testing whether electronic health records can more quickly and accurately track heart and blood vessel problems in Asian American populations.
-
Targeting gut microbes to prevent progression to multiple myeloma
Researchers are testing how specific gut bacteria might trigger immune changes linked to early blood cancer stages and whether targeting these microbes could help prevent progression to multiple myeloma.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer and how it drives aggressiveness
A cancer research project at Fred Hutchinson Cancer Center is studying abnormal circular DNA pieces (ecDNA) that help cancers grow and resist treatment, with the aim of finding ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.